Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

AstraZeneca Shares MATTERHORN Phase III Trial Results For Patients Treated With Neoadjuvant IMFINZI In Combination With Chemotherapy Before Surgery, Followed By Adjuvant IMFINZI In Combination With Chemotherapy, Then IMFINZI Monotherapy.

Author: Benzinga Newsdesk | October 17, 2025 07:09am

More than two thirds of patients treated with IMFINZI-based perioperative regimen were alive at three years

First and only perioperative immunotherapy approach to show survival benefit in this setting

Posted In: AZN